Elevation Oncology (ELEV) announced new preclinical data demonstrating the combination potential of EO-3021, a Claudin 18.2 antibody-drug conjugate or ADC, with VEGFR2 or PD-1 inhibitors. The data will be presented in a poster session at the European Society for Medical Oncology Immuno-Oncology Annual Congress 2024 December 11-13 in Geneva. The company expects to initiate dosing in the combination portion of the ongoing Phase 1 clinical trial of EO-3021 in Q4. The data show: treatment with EO-3021 and DC101 exhibited statistically superior tumor growth inhibition – TGI – vs. either EO-3021 or DC101 alone, 88.2% in combination vs. 20.1% for EO-3021 and 59.2% for DC101 alone; treatment with EO-3021 and a PD-1 inhibitor exhibited statistically superior TGI compared to treatment with either EO-3021 or a PD-1 inhibitor alone; 92% of mice treated with the combination of EO-3021 and a PD-1 inhibitor achieved a complete response vs. 50% mice treated with EO-3021 monotherapy and 17% mice treated with a PD-1 inhibitor alone. Elevation Oncology expects to initiate dosing in the combination portion of its ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024. Additionally, Elevation Oncology continues to enroll patients in the monotherapy dose expansion portion of its ongoing Phase 1 clinical trial and expects to report additional monotherapy data in the first half of 2025.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ELEV:
- Elevation Oncology’s Q3 2024 Highlights and Financial Report
- Elevation Oncology reports Q3 EPS (22c), consensus (20c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
